This is a list of investigational Tourette's syndrome drugs, or drugs that are currently under development for clinical use for the treatment of Tourette's syndrome (TS) but are not yet approved.
Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action [Reference]".
This list was last comprehensively updated in May 2026. It is likely to become outdated with time.
Under development Phase 3 Ecopipam (EBS-101; PSYRX 101; SCH-39166) – dopamine D1 receptor antagonist
Phase 2 Botulinum toxin A (AboBoNT-A; abobotulinumtoxinA; Alluzience; Azzalure; BoNT-A; BTX-A-HAC; BTX-A-HAC NG; Clostridium botulinum toxin type A haemagglutinin complex; Dysport; Reloxin) – acetylcholine release inhibitor and neuromuscular blocking agent CPP-115 – GABA transaminase (GABA-T) inhibitor Dronabinol/palmidrol (THC/PEA; SCI-110; THX OSA01; THX-RS01; THX-110; THX-TS01) – combination of dronabinol (Δ9-THC; cannabinoid CB1 and CB2 receptor agonist) and palmidrol (palmitoylethanolamide (PEA) various actions) EM-221 – phosphodiesterase PDE10A inhibitor Gemlapodect (NOE-105) – phosphodiesterase PDE10A inhibitor Sepranolone (isoallopregnanolone; UC-1010) – GABAA receptor negative allosteric modulator and neurosteroid Valbenazine (Dysval; Ingrezza; MT-5199; NBI-98854; Remleas) – vesicular monoamine transporter 2 (VMAT2) inhibitor
Phase 1 Balipodect (AXS-20; TAK-063) – phosphodiesterase PDE10A inhibitor
Not under development No development reported Seridopidine (ACR343; ACR-343) – dopamine receptor modulator and so-called "dopaminergic stabilizer" Vatiquinone (α-tocotrienol quinone; EPI-743; PTC-743; vincerenone) – arachidonate 15-lipoxygenase (ALOX-15) inhibitor, other actions
Discontinued Acamprosate controlled-release (calcium N-acetylhomotaurinate; SNC-102) – various actions AZD-5213 (AZD5213) – histamine H3 receptor antagonist Brilaroxazine (RP-5000; RP-5063) – atypical antipsychotic (non-selective monoamine receptor modulator) Elcubragistat (ABX-1431; Lu AG06466) – monoacylglycerol lipase (MAGL) inhibitor Onabotulinum toxin A (BoNTA; Botox; botulinum toxin A; GSK-1358820; OnabotA X; OnabotulinumtoxinA X; Vistabel; Vistabex) – acetylcholine release inhibitor and neuromuscular blocking agent Tetrabenazine (BVF-018; Choreazine; Nitoman; Xenazina; Xenazine) – vesicular monoamine transporter 2 (VMAT2) inhibitor
Clinically used drugs Approved drugs Aripiprazole (Abilify; Abilify Asimtufii; Abilify Maintena; Abilify MyCite; Abilitat; Ao Pai; Arlemide; Asimtufii; OPC-14597; OPC-31) – atypical antipsychotic (non-selective monoamine receptor modulator) Deutetrabenazine (Austedo; d6-tetrabenazine; deuterium-substituted tetrabenazine; SD-809; TEV-50717) – vesicular monoamine transporter 2 (VMAT2) inhibitor
Off-label drugs α2-Adrenergic receptor agonists (e.g., clonidine, guanfacine) Antipsychotics (dopamine D2 receptor antagonists) (e.g., fluphenazine, haloperidol, olanzapine, paliperidone, pimozide, risperidone, sertindole, tiapride, ziprasidone) Cannabinoids (e.g., cannabis, Δ9-tetrahydrocannabinol (Δ9-THC)) Dopamine D2-like receptor agonists (e.g., pergolide, pramipexole) GABAB receptor agonists (e.g., baclofen) Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, sertraline) Tricyclic antidepressants (TCAs) (e.g., clomipramine) VMAT2 inhibitors (e.g., tetrabenazine) Others (e.g., botulinum toxin A, clonazepam, levetiracetam, topiramate)
See also List of investigational drugs Management of Tourette syndrome
References
External links AdisInsight - Springer